Enzyme News and Research

RSS

Protalix: New data from taliglucerase alfa, oral GCD trials to be presented at Lysosomal Disease Network Symposium

Protalix BioTherapeutics, Inc., announced today that new clinical data from the switchover trial of taliglucerase alfa in Gaucher disease patients and preclinical data on oral enzyme glucocerebrosidase (oral GCD) will be presented today at the 7th Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2011 in Las Vegas, Nevada.

19 Feb 2011

Genzyme reports 3-year follow-up data from eliglustat tartrate Phase 2 trial for Gaucher disease

Genzyme Corporation today announced three-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for Gaucher disease type 1 known as eliglustat tartrate. Sustained or further improvements were observed across all endpoints, including bone disease, at the three-year timepoint.

19 Feb 2011

New tuberculosis vaccine provides better protection

Nele Festjens and Nico Callewaert of VIB and Ghent University have improved the efficacy of the vaccine for tuberculosis. The new vaccine affords - as already proven in mice - better protection against the disease. The development of a new tuberculosis vaccine is a priority in the fight against the disease which claims the lives of 1.7 million people each year. The current vaccine provides only partial protection.

19 Feb 2011

Medical expert speaks about effects of sugar on human body

With the many forms of sugar available, from table sugar, to high-fructose corn syrup to agave and honey, understanding the differences between sugars and their effects on the body is not all sweet.

18 Feb 2011

Scientists investigate natural chemical compound in sea sponges to create novel anti-cancer drugs

Scientists in London are turning to sea sponges to help them learn more about anti-cancer drugs. Using his £106,079 grant from the Association for International Cancer Research Dr Matthew Fuchter and his team are investigating a naturally-occurring chemical found in the sea sponge.

18 Feb 2011

Cyclacel's CYC065 CDK inhibitor demonstrates potential against breast cancer resistant to trastuzumab

Cyclacel Pharmaceuticals, Inc., today announced the publication of preclinical data in the Proceedings of the National Academy of Sciences (PNAS), demonstrating that cyclin E plays a major role in making Human Epidermal growth factor Receptor 2 positive (HER2+) breast cancer resistant to trastuzumab (Herceptin®), a widely used medicine for breast cancer patients who test positive for HER2.

18 Feb 2011

U.S. FDA approves Corifact to prevent bleeding in people with Factor XIII deficiency

The U.S. Food and Drug Administration today approved Corifact, the first product intended to prevent bleeding in people with the rare genetic defect congenital Factor XIII deficiency.

18 Feb 2011

Conatus commences multi-center CTS-1027 Phase 2b trial for HCV treatment

Conatus Pharmaceuticals Inc. announced today the treatment of the first patient in a multi-center Phase 2b clinical trial evaluating CTS-1027 in combination with Peginterferon Alfa-2a and ribavirin in a treatment experienced, hepatitis C null responder patient population. Safety, tolerability, and antiviral activity of the triple combination will be assessed after up to 48 weeks of therapy.

18 Feb 2011

Positive preliminary data from ongoing PSMA ADC phase 1 study against prostate cancer

Progenics Pharmaceuticals, Inc. today reported positive preliminary data from an ongoing phase 1 study of PSMA ADC, an antibody-drug conjugate designed to selectively deliver chemotherapy to cells that express prostate-specific membrane antigen.

17 Feb 2011

CLC bio releases several desktop software packages for analyzing biological sequence data

Today, CLC bio announced the release of several desktop software packages for analyzing biological sequence data including the popular products such as the CLC Main Workbench 6.0 and CLC DNA Workbench 6.0.

17 Feb 2011

IQWiG publishes results of search update for evidence-based clinical practice guidelines on CHD

On 7 February 2011, the German Institute for Quality and Efficiency in Health Care published the results of a search update for evidence-based clinical practice guidelines on coronary heart disease.

17 Feb 2011

FAK enzyme plays a key role in preparing lung tissue for metastatic development

A Massachusetts General Hospital study has identified a new role for an important enzyme in preparing lung tissue for the development of metastases.

17 Feb 2011

Brain enzyme blocks accumulation of tau proteins, slows down progression of neural degeneration

Increasing puromycin-sensitive aminopeptidase, the most abundant brain peptidase in mammals, slowed the damaging accumulation of tau proteins that are toxic to nerve cells and eventually lead to the neurofibrillary tangles, a major pathological hallmark of Alzheimer's disease and other forms of dementia, according to a study published online in the journal, Human Molecular Genetics.

17 Feb 2011

Deactivation of CRTC1 protein increases lifespan

Substantial evidence suggests that lifespan is increased if an organism restricts its daily calorie intake, a spartan regime that some say works by just making life seem longer. A team of scientists from the Salk Institute of Biological Studies has discovered a molecular switch flipped by hunger that could not only make longevity more appetizing but identify drug targets for patients with aging-related diseases such as type II diabetes or cancer.

17 Feb 2011

Study sheds light on novel functions of certain PCSK enzymes

Recent studies conducted at the Institut de recherches cliniques de Montr-al on a group of PCSK enzymes could have a positive impact on health, from cholesterol to osteoporosis.

17 Feb 2011

Amicus to present additional positive data from Amigal Phase 2 extension study for Fabry disease

Amicus Therapeutics today announced that additional positive data from the ongoing Phase 2 extension study of its investigational drug Amigal™ (migalastat HCl) for Fabry disease will be presented at the Lysosomal Disease Network WORLD Symposium in Las Vegas, Nevada, February 16-18th, 2011.

17 Feb 2011

Study: Overexpression of EZH2 protein promotes breast cancer progression

An essential protein for normal stem cell renewal also promotes the growth of breast cancer stem cells when it's overproduced in those cells, researchers at The University of Texas MD Anderson Cancer Center report in the February edition of Cancer Cell.

16 Feb 2011

Study: High bilirubin levels within normal range linked with reduced risk of respiratory diseases

An analysis of data including more than 500,000 adults indicates that levels in the blood of bilirubin in the normal range but relatively higher were associated with a reduced risk of lung cancer, chronic obstructive pulmonary disease and all-cause death, according to a study in the February 16 issue of JAMA.

15 Feb 2011

EMBL scientists reveal new insights into bacterial enzymes that causes tuberculosis

In a paper published today in PNAS, scientists from the European Molecular Biology Laboratory in Hamburg, Germany, reveal new insights into the workings of enzymes from a group of bacteria including Mycobacterium tuberculosis, the bacterium that causes tuberculosis.

15 Feb 2011

Researchers use computers to capture chemical signal structure that triggers metastatic cancer

In cancer and other pathological diseases, researchers are discovering that packaging is important: specifically, how DNA - about two meters long when unwound and stretched - coils up and compacts neatly inside the nucleus of a cell.

15 Feb 2011

Enzyme News and Research

Protalix: New data from taliglucerase alfa, oral GCD trials to be presented at Lysosomal Disease Network Symposium

Genzyme reports 3-year follow-up data from eliglustat tartrate Phase 2 trial for Gaucher disease

New tuberculosis vaccine provides better protection

Medical expert speaks about effects of sugar on human body

Scientists investigate natural chemical compound in sea sponges to create novel anti-cancer drugs

Cyclacel's CYC065 CDK inhibitor demonstrates potential against breast cancer resistant to trastuzumab

U.S. FDA approves Corifact to prevent bleeding in people with Factor XIII deficiency

Conatus commences multi-center CTS-1027 Phase 2b trial for HCV treatment

Positive preliminary data from ongoing PSMA ADC phase 1 study against prostate cancer

CLC bio releases several desktop software packages for analyzing biological sequence data

IQWiG publishes results of search update for evidence-based clinical practice guidelines on CHD

FAK enzyme plays a key role in preparing lung tissue for metastatic development

Brain enzyme blocks accumulation of tau proteins, slows down progression of neural degeneration

Deactivation of CRTC1 protein increases lifespan

Study sheds light on novel functions of certain PCSK enzymes

Amicus to present additional positive data from Amigal Phase 2 extension study for Fabry disease

Study: Overexpression of EZH2 protein promotes breast cancer progression

Study: High bilirubin levels within normal range linked with reduced risk of respiratory diseases

EMBL scientists reveal new insights into bacterial enzymes that causes tuberculosis

Researchers use computers to capture chemical signal structure that triggers metastatic cancer

Biochemistry eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News